Levilimab Biosimilar – Anti-IL6R mAb – Research Grade

Description of Levilimab Biosimilar - Anti-IL6R mAb - Research Grade

Introduction to Levilimab Biosimilar – Anti-IL6R mAb

Levilimab Biosimilar is a monoclonal antibody (mAb) that targets the interleukin-6 receptor (IL6R). It is a research grade antibody that has shown promising results in pre-clinical and clinical studies as a potential therapeutic for various inflammatory and autoimmune diseases. In this article, we will dive into the structure, activity, and potential applications of Levilimab Biosimilar.

Structure of Levilimab Biosimilar

Levilimab Biosimilar is a biosimilar version of the anti-IL6R mAb, tocilizumab. It is a fully humanized IgG1 kappa monoclonal antibody with a molecular weight of approximately 148 kDa. The antibody is composed of two heavy chains and two light chains, each containing a variable and constant region.

The variable region of Levilimab Biosimilar is responsible for its specificity and binding to IL6R. It recognizes and binds to the extracellular domain of IL6R, preventing the binding of interleukin-6 (IL-6) and subsequent signaling through the IL-6/IL6R complex. This inhibits the pro-inflammatory effects of IL-6, making Levilimab Biosimilar a potential therapeutic for IL-6 driven diseases.

Activity of Levilimab Biosimilar

The main activity of Levilimab Biosimilar is its ability to block the IL-6 signaling pathway. IL-6 is a cytokine that plays a crucial role in the immune response, inflammation, and tissue regeneration. However, dysregulation of IL-6 signaling has been linked to various diseases, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS).

By binding to IL6R, Levilimab Biosimilar prevents the binding of IL-6 and inhibits its downstream signaling. This leads to a decrease in the production of pro-inflammatory cytokines and chemokines, as well as a reduction in the recruitment and activation of immune cells. Overall, Levilimab Biosimilar helps to restore the balance of the immune system and reduce inflammation.

Potential Applications of Levilimab Biosimilar

Levilimab Biosimilar has shown promising results in pre-clinical and clinical studies as a potential therapeutic for various inflammatory and autoimmune diseases. Some of the potential applications of Levilimab Biosimilar include:

Rheumatoid Arthritis (RA) RA is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain and stiffness. IL-6 has been identified as a key player in the pathogenesis of RA. Levilimab Biosimilar has shown efficacy in reducing the signs and symptoms of RA in clinical trials, making it a potential treatment option for this disease.

Cytokine Release Syndrome (CRS)

CRS is a severe and potentially life-threatening complication that can occur in response to certain immunotherapies. It is characterized by an excessive release of pro-inflammatory cytokines, including IL-6. Levilimab Biosimilar has shown promising results in reducing the severity of CRS in pre-clinical studies, making it a potential treatment for this condition.

Systemic Juvenile Idiopathic Arthritis (SJIA)

SJIA is a rare form of juvenile idiopathic arthritis (JIA) that is characterized by systemic inflammation and high levels of IL-6. Levilimab Biosimilar has shown efficacy in reducing the symptoms of SJIA in clinical trials, making it a potential treatment option for this disease.

Other Inflammatory and Autoimmune Diseases

IL-6 has been implicated in the pathogenesis of various other inflammatory and autoimmune diseases, such as psoriasis, Crohn’s disease

Levilimab Biosimilar - Anti-IL6R mAb binds to CD126 Recombinant Protein in indirect ELISA Assay

Immobilized CD126 Recombinant Protein (cat. No.PX-P4104) at 0.5µg/mL (100µL/well) can bind to Levilimab Biosimilar - Anti-IL6R mAb (cat. No.PX-TA1545) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450